Biotech and Pharma Industry Eagerly Embraces Antibody-Drug Conjugates for Cancer Treatment Growth
The JPMorgan Healthcare Conference held in San Francisco spotlighted the growing interest and enthusiasm within the biotech and pharmaceutical industry for antibody-drug conjugates (ADCs), a class of cancer drugs demonstrating significant promise. ADCs deliver targeted cancer-killing therapies, minimizing damage to...